For each COVID-19 hospitalization prevented in previously uninfected young adults, the data indicate that 18 to 98 serious adverse events are likely to occur, including 1.7 to 3.0 booster-associated myocarditis cases in males, and 1,373 to 3,234 cases of grade ≥3 reactogenicity, which interferes with daily activities.
